FIELD: medicine.
SUBSTANCE: invention represents medication for treating demyelinating diseases of nervous system, containing stephaglabrine sulphate, which favours recovery of myelin sheath of nerve fibre, its application and method of treatment.
EFFECT: increase of efficiency of medication medicinal activity, possibility to use it in low doses, reduction of side effects number, acceleration and increasing efficiency of treatment of demyelinating diseases of nervous system.
5 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ACTIVE DRUG INGREDIENT, DRUG, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF DEMYELINATING DISEASES OF LIVING ORGANISM, INCLUDING DISEASE PREVENTION | 2015 |
|
RU2631887C2 |
| TREATMENT OF DEMYELINATING DISEASES | 2019 |
|
RU2805061C2 |
| COMPLEX OF MYELIN LIPIDS OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM OF ANIMALS FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DEMYELINATING DISORDERS AND METHODS FOR ITS APPLICATION | 2019 |
|
RU2761617C2 |
| THERAPY OF INFLAMMATORY DISEASES | 2007 |
|
RU2440110C2 |
| METHOD FOR TREATING THE CASES OF DEMYELINIZING DISEASES | 2001 |
|
RU2218166C2 |
| METHOD FOR DETERMINING AUTOIMMUNE PROCESS | 0 |
|
SU1709220A1 |
| TREATMENT OF MULTIPLE SCLEROSIS ACCORDING TO THE METHOD OF KRIVOPALOV-MOSKVIN | 2018 |
|
RU2702120C1 |
| METHOD FOR TREATING THE PATIENTS SUFFERING FROM AUTOIMMUNE DISEASES | 1999 |
|
RU2159635C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING THERAPEUTIC EFFECT ON DEMYELINATING DISEASES (VERSIONS) | 2015 |
|
RU2611415C1 |
| EGF/GHRP-6 COMBINATION FOR CENTRAL NERVOUS SYSTEM NEUROREGENERATION AFTER AUTOIMMUNNE DAMAGE | 2006 |
|
RU2403913C2 |
